Nymox Releases New Study Data from U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep For Men Given Nymox Drug
HASBROUCK HEIGHTS, N.J., December 16, 2008--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced new results from a recently completed multi-center U.S. clinical study of NX-1207, the Company’s innovative investigational drug for benign prostatic hyperplasia (BPH). The evidence indicates that NX-1207 can markedly reduce the incidence of nocturia, a particularly bothersome symptom of nighttime urination associated with BPH. After 90 days, subjects treated with a therapeutic dose of NX-1207 had a mean 49% reduction in nocturia symptoms, which was statistically significant compared to baseline (p<.001).
Nocturia (having to repeatedly get up in the night to urinate) is a common symptom of BPH. Severe nocturia frequently leads to chronic sleep loss and, in turn, fatigue, memory deficits, mood changes including depression, and increased risk of long term medical problems. Untreated BPH can also progress to more serious urinary tract conditions.
NX-1207 has been shown to improve the signs and symptoms of BPH, producing an improvement which has been statistically significantly better than double-blinded placebo and study controls and is higher than the improvement reported for approved drugs for BPH. NX-1207 involves a new targeted approach to the treatment of BPH. The drug is administered by a urologist in an office setting directly into the zone of the prostate where the enlargement occurs, and the injection takes only a few minutes and involves little or no pain or discomfort. NX-1207 has not been found to have the sexual, blood pressure, or other side effects of the approved drugs.
BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age.
This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. ###
Posted: December 2008